Skip to main content
SpringerLink
Log in

Investigating Oral Absorption of Carbamazepine in Pediatric Populations

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Prediction of the pharmacokinetics of orally administered drugs in children is of importance to optimize the efficacy and safety of pediatric medicines. Physiologically based pharmacokinetic (PBPK) models can be helpful for this purpose. However, application of these tools is limited by significant knowledge gaps regarding the physiological and anatomical changes which occur with age. This study aimed at investigating the age-dependent differences in oral absorption of a poorly soluble model compound, carbamazepine (CBZ) in children, infants, and neonates. We developed an oral absorption model in GastroPlus® and, after evaluation of the PBPK model for adults, extrapolation to younger ages was verified with clinical data and sensitivity analyses were applied for uncertain model parameters. We found that age-based scaling of physiological parameters, with clearance in particular, was important to obtain adequate simulation results. The sensitivity analysis revealed that CBZ absorption was influenced by solubility, particle radius, and small intestinal transit time depending on the pediatric age group and CBZ dose. However, in vitro dissolution testing using proposed pediatric biorelevant media suggested no major age dependency of dissolution kinetics. Such better understanding of oral absorption in pediatric patients is required to improve the prediction of exposure in children and the confidence in oral biopharmaceutical tools.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Best Pharmaceuticals for Children Act, January 4, 2002 (Public Law No. 107–109).

  2. Pediatric Research Equity Act, December 3, 2003 (Public Law No. 108–155).

  3. Batchelor HK, Fotaki N, Klein S. Paediatric oral biopharmaceutics: key considerations and current challenges. Adv Drug Deliv Rev. 2014;73:102–26.

    Article  CAS  PubMed  Google Scholar 

  4. Batchelor HK, Kendall R, Desset-Brethes S, Alex R, Ernest TB. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. Eur J Pharm Biopharm. 2013;85:833–42.

    Article  CAS  PubMed  Google Scholar 

  5. Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, et al. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014;133(3):563–7.

    Article  PubMed  Google Scholar 

  6. Jamei M. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Curr Pharmacol Rep. 2016;2:161–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012;91(5):926–31.

    Article  CAS  PubMed  Google Scholar 

  8. Grillo JA. Pediatric applications of PBPK modeling and simulation in drug regulatory science: where are we now? AAPS Annual Meeting and Exposition. San Diego, USA; 2014.

  9. Batchelor H, Ernest T, Flanagan T, Klein S, Turner R, Fotaki N, et al. Towards the development of a paediatric biopharmaceutics classification system: results of a survey of experts. Int J Pharm. 2016;511(2):1151–7.

    Article  CAS  PubMed  Google Scholar 

  10. Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop–Pediatric Biopharmaceutics Classification System Working Group. Clin Ther. 2012;34:S11–23.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Villiger A, Stillhart C, Parrott N, Kuentz M. Using physiologically based pharmacokinetic (PBPK) modelling to gain insights into the effect of physiological factors on oral absorption in paediatric populations. AAPS J. 2016;18(4):933–47.

    Article  CAS  PubMed  Google Scholar 

  12. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–62.

    Article  CAS  PubMed  Google Scholar 

  13. Cristofoletti R, Charoo NA, Dressman JB. Exploratory investigation of the limiting steps of oral absorption of fluconazole and ketoconazole in children using an in silico pediatric absorption model. J Pharm Sci. 2016;105(9):2794–803.

    Article  CAS  PubMed  Google Scholar 

  14. Maharaj AR, Edginton AN, Fotaki N. Assessment of age-related changes in pediatric gastrointestinal solubility. Pharm Res. 2016;33(1):52–71.

    Article  CAS  PubMed  Google Scholar 

  15. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47(11):1969–79.

    Article  CAS  PubMed  Google Scholar 

  16. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet. 1986;11(3):177–98.

    Article  CAS  PubMed  Google Scholar 

  17. Tulloch JK, Carr RR, Ensom MH. A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. J Pediatr Pharmacol Ther. 2012;17(1):31–44.

    PubMed  PubMed Central  Google Scholar 

  18. Patsalos PN. Carbamazepine. In: Patsalos PN, editor. Antiepileptic drug interactions. A clinical guide. 2nd ed. London: Springer; 2013. p. 11–21.

    Chapter  Google Scholar 

  19. Rawlins MD, Collste P, Bertilsson L, Palmér L. Distribution and elimination kinetics of carbamazepine in man. Eur J Clin Pharmacol. 1975;8(2):91–6.

    Article  CAS  PubMed  Google Scholar 

  20. Gérardin AP, Abadie FV, Campestrini JA, Theobald W. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacol Biopharm. 1976;4(6):521–35.

    Article  Google Scholar 

  21. Anttila M, Kahela P, Panelius M, Yrjänö T, Tikkanen R, Aaltonen R. Comparative bioavailability of two commercial preparations of carbamazepine tablets. Eur J Clin Pharmacol. 1979;15:421–5.

    Article  CAS  PubMed  Google Scholar 

  22. De Aurajo Ferreira AA, Coelho Guerra GB, da Silva SG, Dibildox E, Perez-Urizar J, et al. Comparative bioavailability of two extemporaneous solid formulations of carbamazepine against the innovator in Mexican healthy subjects. J Bioequiv Availab. 2014;6:2.

    Google Scholar 

  23. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR, Shah VP. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res. 1992;9(12):1612–6.

    Article  CAS  PubMed  Google Scholar 

  24. Revankar SN, Desai ND, Bhatt AD, Bolar HV, Sane SP, Gupta C, et al. Comparison of absorption rate and bioavailability of two brands of carbamazepine. J Assoc Physicians India. 1999;47(7):699–702.

    CAS  PubMed  Google Scholar 

  25. Kayali A, Tuğlular I, Ertaş M. Pharmacokinetics of carbamazepine. Part I: a new bioequivalency parameter based on a relative bioavailability trial. Eur J Drug Metab Pharmacokinet. 1994;19(4):319–25.

    Article  CAS  PubMed  Google Scholar 

  26. Strandjord RE, Johannessen SI. A preliminary study of serum carbamazepine levels in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther. 1975:181–8.

  27. Morselli PL, Gerna M, de Maio D, Zanda G, Viani F, Garattini S. Pharmacokinetic studies on carbamazepine in volunteers and epileptic patients. Clin Pharmacol Anti-Epileptic Drugs. 1975:166–80.

  28. Chan KK, Sawchuk RJ, Thompson TA, Redalieu E, Wagner WE Jr, LeSher AR, et al. Bioequivalence of carbamazepine chewable and conventional tablets: single-dose and steady-state studies. J Pharm Sci. 1985;74(8):866–70.

    Article  CAS  PubMed  Google Scholar 

  29. Kovacević I, Parojcić J, Homsek I, Tubić-Grozdanis M, Langguth P. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm. 2009;6(1):40–7.

    Article  PubMed  Google Scholar 

  30. Cotter LM, Eadie MJ, Hooper WD, Lander CM, Smith GA, Tyrer JH. The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol. 1977;12(6):451–6.

    Article  CAS  PubMed  Google Scholar 

  31. Pynnönen S, Mäntylä R, Iisalo E. Bioavailability of four different pharmaceutical preparations of carbamazepine. Acta Pharmacol Toxicol (Copenh). 1978;43(4):306–10.

    Article  Google Scholar 

  32. Olling M, Mensinga TT, Barends DM, Groen C, Lake OA, Meulenbelt J. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos. 1999;20(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  33. Bhatia SC, Bhatt AD, Bakshi RJ, Revankar SN, Bharucha ED, Doshi KJ, et al. Comparative bioavailability with two brands of carbamazepine-Tegretol and Mazetol in healthy volunteers. J Assoc Physicians India. 1988;36(10):611–2.

    CAS  PubMed  Google Scholar 

  34. Neuvonen PJ. Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol. 1985;23(4):226–32.

    CAS  PubMed  Google Scholar 

  35. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther. 1983;33(4):460–4.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang X, Lionberger RA, Davit BM, Yu LX. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J. 2011;13(1):59–71.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM. Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther. 1975;17(6):657–68.

    Article  CAS  PubMed  Google Scholar 

  38. Johannessen SI, Henriksen O, Munthe-Kaas AW, Salvesen B. Serum concentration profile studies of tablets and suppositories of valproate and carbamazepine in healthy subjects and patients with epilepsy. In: Levy RH, Pitlick WH, Eichelbaum M, Meijer J, editors. Metabolism of antiepileptic drugs. New York: Raven Press; 1984. p. 61–71.

    Google Scholar 

  39. Dam M, Christiansen J, Kristensen CB, Helles A, Jaegerskou A, Schmiegelow M. Carbamazepine: a clinical biopharmaceutical study. Eur J Clin Pharmacol. 1981;20(1):59–64.

    Article  CAS  PubMed  Google Scholar 

  40. Cotter LM, Smith G, Hooper WD, Tyrer JH, Eadie MJ. The bioavailability of carbamazepine. Proc Aust Assoc Neurol. 1975;12:123–8.

    CAS  PubMed  Google Scholar 

  41. Maas B, Garnett WR, Pellock JM, Comstock TJ. A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation. Ther Drug Monit. 1987;9(1):28–33.

    Article  CAS  PubMed  Google Scholar 

  42. Sumi M, Watari N, Umezawa O, Kaneniwa N. Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans. Aust J Pharm. 1987;10(11):652–61.

    CAS  Google Scholar 

  43. Kaneniwa N, Umezawa O, Watari N, Kawakami K, Asami H, Sumi M. Bioavailability and dissolution test of commercial carbamazepine tablets. Yakugaku Zasshi 1984;104(1):83–90. Japanese.

  44. Paxton JW, Donald RA. Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum. Clin Pharmacol Ther. 1980;28(5):695–702.

    Article  CAS  PubMed  Google Scholar 

  45. Riad LE, Chan KK, Wagner WE Jr, Sawchuk RJ. Simultaneous first- and zero-order absorption of carbamazepine tablets in humans. J Pharm Sci. 1986;75(9):897–900.

    Article  CAS  PubMed  Google Scholar 

  46. Jung H, Milán RC, Girard ME, Montoya MA. Bioequivalence study of carbamazepine tablets: in vitro/in vivo correlation. Int J Pharm. 1997;152(1):37–44.

    Article  CAS  Google Scholar 

  47. Neuvonen PJ, Tokola O. Bioavailability of rectally administered carbamazepine mixture. Br J Clin Pharmacol. 1987;24(6):839–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Hooper WD, King AR, Patterson M, Dickinson RG, Eadie MJ. Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. Ther Drug Monit. 1985;7(1):36–40.

    Article  CAS  PubMed  Google Scholar 

  49. Wada JA, Troupin AS, Friel P, Remick R, Leal K, Pearmain J. Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine. Epilepsia. 1978;19(3):251–5.

    Article  CAS  PubMed  Google Scholar 

  50. Graves NM, Kriel RL, Jones-Saete C, Cloyd JC. Relative bioavailability of rectally administered carbamazepine suspension in humans. Epilepsia. 1985;26(5):429–33.

    Article  CAS  PubMed  Google Scholar 

  51. Popović J, Mikov M, Jakovljevic V. Pharmacokinetics of carbamazepine derived from a new tablet formulation. Eur J Drug Metab Pharmacokinet. 1995;20(4):297–300.

    Article  PubMed  Google Scholar 

  52. Kauko K, Tammisto P. Comparison of two generically equivalent carbamazepine preparations. Ann Clin Res. 1974;6(Suppl 11):21–5.

    Google Scholar 

  53. Bano G, Raina RK, Sharma DB. Pharmacokinetics of carbamazepine in protein energy malnutrition. Pharmacology. 1986;32(4):232–6.

    Article  CAS  PubMed  Google Scholar 

  54. Rey E, d'Athis P, de Lauture D, Dulac O, Aicardi J, Olive G. Pharmacokinetics of carbamazepine in the neonate and in the child. Int J Clin Pharmacol Biopharm. 1979;17(2):90–6.

    CAS  PubMed  Google Scholar 

  55. MacKintosh DA, Baird-Lampert J, Buchanan N. Is carbamazepine an alternative maintenance therapy for neonatal seizures? Dev Pharmacol Ther. 1987;10(2):100–6.

    Article  CAS  PubMed  Google Scholar 

  56. Miles MV, Lawless ST, Tennison MB, Zaritsky AL, Greenwood RS. Rapid loading of critically ill patients with carbamazepine suspension. Pediatrics. 1990;86(2):263–6.

    CAS  PubMed  Google Scholar 

  57. European Medicines Agency. ICH Topic E 11: Clinical investigation of medicinal products in the paediatric population. CPMP/ICH/2711/99. London; 2001.

  58. Simulations Plus, Inc. GastroPlus version 9.0: simulation software for drug discovery and development (user manual). 2015; Lancaster, CA.

  59. Parrott N, Lave T. Applications of physiologically based absorption models in drug discovery and development. Mol Pharm. 2008;5(5):760–75.

    Article  CAS  PubMed  Google Scholar 

  60. Heikkinen AT, Baneyx G, Caruso A, Parrott N. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates—an evaluation and case study using GastroPlus. Eur J Pharm Sci. 2012;47(2):375–86.

    Article  CAS  PubMed  Google Scholar 

  61. Jones H, Parrott N, Ohlenbusch G, Lavé T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharm. 2006;45(12):1213–26.

    Article  CAS  Google Scholar 

  62. Parrott N, Lave T. Computer models for predicting drug absorption. In: Dressman J, Reppas C, editors. Oral drug absorption—prediction and assessment. Boca Raton: CRC Press; 2010. p. 338–55.

    Google Scholar 

  63. Jorga K, Chavanne C, Frey N, Lave T, Lukacova V, Parrott N, et al. Bottom-up meets top-down: complementary physiologically based pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children. Clin Pharmacol Ther. 2016;100(6):761–9.

    Article  CAS  PubMed  Google Scholar 

  64. Lukacova V, Goelzer P, Reddy M, Greig G, Reigner B, Parrott N. A physiologically based pharmacokinetic model for ganciclovir and its prodrug valganciclovir in adults and children. AAPS J. 2016;18(6):1453–63.

    Article  CAS  PubMed  Google Scholar 

  65. Haddad S, Restieri C, Krishnan K. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Environ Health A. 2001;64(6):453–64.

    Article  CAS  PubMed  Google Scholar 

  66. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005;11(12):1481–93.

    Article  PubMed  Google Scholar 

  67. McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSciTech. 2002;4(1):E4.

    Google Scholar 

  68. Rubin MI, Bruck E, Rapport M. Maturation of renal function in childhood: clearance studies. J Clin Invest. 1949;28(5 Pt 2):1144–62.

    Article  CAS  PubMed Central  Google Scholar 

  69. Yanowitz TD, Yao AC, Pettigrew KD, Werner JC, Oh W, Stonestreet BS. Postnatal hemodynamic changes in very-low-birth weight infants. J Appl Physiol. 1999;87(1):370–80.

    CAS  PubMed  Google Scholar 

  70. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931–56.

    Article  CAS  PubMed  Google Scholar 

  71. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407–84.

    Article  CAS  PubMed  Google Scholar 

  72. LL de Zwart, CJM Rompelberg, AJAM Sips, Welink J, JGM van Engelen. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. A review of literature. Bilthoven (NL): National Institute of Public Health and the Environment; 1999 Report No.: 623860 010.

  73. Van Den Driessche M, Van Malderen N, Geypens B, Ghoos Y, Veereman-Wauters G. Lactose-[13C]ureide breath test: a new, noninvasive technique to determine orocecal transit time in children. J Pediatr Gastroenterol Nutr. 2000;31(4):433–8.

    Article  Google Scholar 

  74. Zhang SC, Wang WL, Bai YZ, Yuan ZW, Wang W. Determination of total and segmental colonic transit time in constipated children. Zhonghua Er Ke Za Zhi 2003;41(3):176–179. Chinese.

  75. Bautista Casasnovas A, Varela Cives R, Villanueva Jeremias A, Castro-Gago M, Cadranel S, Tojo SR. Measurement of colonic transit time in children. J Pediatr Gastroenterol Nutr. 1999;13(1):42–5.

    Article  Google Scholar 

  76. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.

    Article  CAS  PubMed  Google Scholar 

  77. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP). Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/PEG194810/2005. London; 2006.

  78. Reith DM, Hooper WD, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Pharmacodyn. 2001;28(1):79–92.

    Article  CAS  PubMed  Google Scholar 

  79. Delgado Iribarnegaray MF, Santo Bueldga D, García Sánchez MJ, Otero MJ, Falcão AC, Domínguez-Gil A. Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther Drug Monit. 1997;19(2):132–9.

    Article  CAS  PubMed  Google Scholar 

  80. Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol. 1996;36(8):752–9.

    Article  CAS  PubMed  Google Scholar 

  81. Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol. 1998;54(4):359–62.

    Article  CAS  PubMed  Google Scholar 

  82. Table for body surface area—body weight correlation in children. [Internet] National Institute for Health and Care Excellence Great Britain [cited 21 Sep 2016]. Available from: https://www.evidence.nhs.uk/formulary/bnfc/current/body-surface-area-in-children.

  83. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15(5):698–705.

    Article  CAS  PubMed  Google Scholar 

  84. biorelevant.com [Internet]. London: Instructions for preparation of FaSSIF, FeSSIF, and FaSSGF [cited 3 June 2017]. Available from: https://biorelevant.com/fassif-fessif-fassgf/how-to-make/.

  85. Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2015;2(10):585.

    Google Scholar 

  86. Magnusson M, et al. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther. 2008;84(1)

  87. Bertilsson L, et al. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther. 1980;27(1):83–8.

    Article  CAS  PubMed  Google Scholar 

  88. Biochemical pharmacology Volume 47, Issue 11, 1 June 1994, Pages 1969–1979.

  89. Wang P, et al. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res. 2015;117:52–7.

    Article  CAS  PubMed  Google Scholar 

  90. Gandhi SV, Rodriguez W, Khan M, Polli JE. Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs. AAPS PharmSciTech. 2014;15(3):601–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Shawahna R. Pediatric biopharmaceutical classification system: using age-appropriate initial gastric volume. AAPS J. 2016;18(3):728–36.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Nicolas JM, Bouzom F, Hugues C, Ungell AL. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. Biopharm Drug Dispos. 2017;38(3):209–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Formulation Research & Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland

    Philip Kohlmann & Cordula Stillhart

  2. Institute of Pharmaceutical Technology, University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland

    Martin Kuentz

  3. Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland

    Neil Parrott

Authors
  1. Philip Kohlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cordula Stillhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Kuentz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neil Parrott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil Parrott.

Electronic Supplementary Material

ESM 1

(DOCX 1580 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kohlmann, P., Stillhart, C., Kuentz, M. et al. Investigating Oral Absorption of Carbamazepine in Pediatric Populations. AAPS J 19, 1864–1877 (2017). https://doi.org/10.1208/s12248-017-0149-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-017-0149-6

KEY WORDS

Search

Navigation